Dravet syndrome, a diagnostic challenge: Case Report

Authors

DOI:

https://doi.org/10.55204/trc.v3i2.e178

Keywords:

Dravet's Syndrome, Epilepsy, Seizures, SCN1A

Abstract

Abstract. Dravet syndrome is a severe epileptic encephalopathy of very low incidence (1 pe 20,000-40,000), it is classified as rare and of little medical knowledge and suspicion, which makes its diagnosis difficult. It is an alteration in the SCN1A gene, the main encoder of the alpha 1 subunit of the sodium channel. Case presentation: 6-month-old female patient, born by cesarean section, normal pregnancy course, without complications, mother with a history of a previous abortion, no significant family history and motor development according to age. She went to the emergency room for presenting an unquantified thermal rise and seizure, which occurred after the third dose of pentavalent vaccine corresponding to her age, this not being a triggering factor for the seizure. Having very frequent episodes and not obtaining an adequate control, several diagnostic tests are performed including genetic studies of WES to reach a treatment according to a specific diagnosis, for this reason the parents of the minor decide to go to countries of technology to perform this type of diagnosis. The relevance of the case lies in demonstrating that Dravet syndrome is an underdiagnosed and inadequately treated disease, however, currently the use of tools, especially genetic methods and early control prevents patients from presenting several repeated episodes and improves their quality of life.

   Keywords: Dravet's Syndrome, Epilepsy, Seizures, SCN1A

Downloads

Download data is not yet available.

References

Vargas JMS, Pinzon-Salamanca JY, Laverde-Hernández J, Ayala-Olaya D, Gonzalez-Moreno AM. Mutación en el gen SCN9A asociado con el síndrome de Dravet: presentación de un caso pediátrico. Revista Ciencias de la Salud [Internet]. 11 de febrero de 2022 [citado 15 de marzo de 2023];20(1). Disponible en: https://revistas.urosario.edu.co/index.php/revsalud/index

Editores V. Neurología.com [Internet]. [citado 15 de marzo de 2023]. Disponible en: https://neurologia.com/articulo/articulo/2018189

Wheless JW, Fulton SP, Mudigoudar BD. Dravet Syndrome: A Review of Current Management. Pediatr Neurol. junio de 2020;107:28-40.

Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 21 de diciembre de 2019;394(10216):2243-54.

Ortiz B, Jaramillo Y, Rojas C. Síndrome epiléptico ligado al cromosoma X por mutación de la protocaderina 19 (OMIM 300088) asociado con leucoencefalopatía y tractopatía posterior reversible. Biomédica. 1 de diciembre de 2018;38(4):463-6.

Andrade DM, Berg AT, Hood V, Knupp KG, Koh S, Laux L, et al. Dravet syndrome: A quick transition guide for the adult neurologist. Epilepsy Res. noviembre de 2021;177:106743.

Gil-Nagel A, Sanchez-Carpintero R, San Antonio V, Mistry A, Barker G, Shepherd J, et al. Ascertaining the epidemiology, patient flow and disease management for Dravet syndrome in Spain. Rev Neurol. 16 de enero de 2019;68(2):75-81.

Pérez AB, Moreno N. Síndrome de Dravet. Salus. diciembre de 2015;19(3):27-30.

Aledo-Serrano Á, Mingorance A, Villanueva V, García-Peñas JJ, Gil-Nagel A, Boronat S, et al. The Charlotte Project: Recommendations for patient-reported outcomes and clinical parameters in Dravet syndrome through a qualitative and Delphi consensus study. Front Neurol. 1 de septiembre de 2022;13:975034.

Brunklaus A. Dravet syndrome - Time to consider the burden beyond the disease. Eur J Paediatr Neurol. mayo de 2019;23(3):344.

Ding J, Li X, Tian H, Wang L, Guo B, Wang Y, et al. SCN1A Mutation-Beyond Dravet Syndrome: A Systematic Review and Narrative Synthesis. Front Neurol. 2021;12:743726.

Myers KA, Davey MJ, Ching M, Ellis C, Grinton BE, Roten A, et al. Randomized Controlled Trial of Melatonin for Sleep Disturbance in Dravet Syndrome: The DREAMS Study. J Clin Sleep Med. 15 de octubre de 2018;14(10):1697-704.

Vaudagna M, Vergara G, Martínez A, Canonero I, Sfaello Z, Sfaello I. Encefalopatía epiléptica de inicio temprano, pdch19. Methodo Investigación Aplicada a las Ciencias Biológicas. 2 de abril de 2019;4:27-8.

Scheffer IE, Nabbout R. SCN1A-related phenotypes: Epilepsy and beyond. Epilepsia. diciembre de 2019;60 Suppl 3:S17-24.

Strzelczyk A, Schubert-Bast S. A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication. CNS Drugs. 2022;36(3):217-37.

Cook M, Murphy M, Bulluss K, D’Souza W, Plummer C, Priest E, et al. Anti-seizure therapy with a long-term, implanted intra-cerebroventricular delivery system for drug-resistant epilepsy: A first-in-man study. EClinicalMedicine. 3 de mayo de 2020;22:100326.

Gauthier AC, Mattson RH. Clobazam: A Safe, Efficacious, and Newly Rediscovered Therapeutic for Epilepsy. CNS Neurosci Ther. julio de 2019;21(7):543-8.

Brigo F, Igwe SC, Bragazzi NL. Stiripentol add‐on therapy for drug‐resistant focal epilepsy. Cochrane Database Syst Rev. 26 de mayo de 2020;2020(5):CD009887.

Mei D, Cetica V, Marini C, Guerrini R. Dravet syndrome as part of the clinical and genetic spectrum of sodium channel epilepsies and encephalopathies. Epilepsia. diciembre de 2019;60 Suppl 3:S2-7.

Ruiz G, Pilar G del. Encefalopatías epilépticas de inicio en recién nacidos y lactantes. Medicina (Buenos Aires). octubre de 2022;82:13-8.

Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R, et al. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial. JAMA Neurol. 1 de marzo de 2020;77(3):300-8.

Howell KB, Freeman JL, Mackay MT, Fahey MC, Archer J, Berkovic SF, et al. The severe epilepsy syndromes of infancy: A population-based study. Epilepsia. febrero de 2021;62(2):358-70.

Venegas Silva V, García Venegas E, Repetto Lisboa MG, Barroso Ramos E, Lapunzina Badia P, Venegas Silva V, et al. Variante patogénica en el gen PCDH19 en una paciente con epilepsia y discapacidad cognitiva. Revista chilena de pediatría. octubre de 2020;91(5):761-6.

Brunklaus A, Brünger T, Feng T, Fons C, Lehikoinen A, Panagiotakaki E, et al. The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications. Brain. 21 de noviembre de 2022;145(11):3816-31.

Wirrell EC, Hood V, Knupp KG, Meskis MA, Nabbout R, Scheffer IE, et al. International consensus on diagnosis and management of Dravet syndrome. Epilepsia. julio de 2022;63(7):1761-77.

Anwar A, Saleem S, Patel UK, Arumaithurai K, Malik P. Dravet Syndrome: An Overview. Cureus [Internet]. junio de 2019 [citado 15 de marzo de 2023];11(6). Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713249/

Aledo-Serrano A, García-Morales I, Toledano R, Jiménez-Huete A, Parejo B, Anciones C, et al. Diagnostic gap in genetic epilepsies: A matter of age. Epilepsy Behav. octubre de 2020;111:107266.

Brown A, Arpone M, Schneider AL, Micallef S, Anderson VA, Scheffer IE. Cognitive, behavioral, and social functioning in children and adults with Dravet syndrome. Epilepsy Behav. noviembre de 2020;112:107319.

de Lange IM, Gunning B, Sonsma ACM, van Gemert L, van Kempen M, Verbeek NE, et al. Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A-related seizure phenotypes. Epilepsia. junio de 2018;59(6):1154-65.

Downloads

Published

2023-05-15

Issue

Section

Health Sciences

How to Cite

Koppel Peralta, I. C., Ochoa Bravo, A. C., Guartazaca Guerrero, E. P., & Castillo Solano, F. D. (2023). Dravet syndrome, a diagnostic challenge: Case Report. Tesla Revista Científica, 3(2), e178. https://doi.org/10.55204/trc.v3i2.e178